Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Stopped The study was terminated by sponsor as the development program was discontinued due to outcome of phase III Trilynx study.

Conditions

• Head and Neck Cancer

Interventions

• DRUG: Xevinapant
• RADIATION: IMRT
• DRUG: Placebo

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]